Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: Mechanisms and interventions

Transfusion

Volumn 56, Issue 1, 2016, Pages 91-100

  Waterman, Hayley R ^a   Kapp, Linda M ^a   Munday, Adam ^a   Odem Davis, Katherine ^a   Zimring, James C ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Bloodworks NW Research Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALLOANTIBODY; COMPLEMENT COMPONENT C3; FC RECEPTOR; FIBRINOGEN RECEPTOR; HEMOGLOBIN GAMMA CHAIN; HLA ANTIGEN; BIOLOGICAL MARKER; HISTOCOMPATIBILITY ANTIGEN;

ALLOIMMUNIZATION; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; EARLY INTERVENTION; HLA SYSTEM; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PLATELET TRANSFUSION REFRACTORINESS; REGULATORY MECHANISM; THROMBOCYTE FUNCTION AND CHARACTERISTICS; THROMBOCYTE TRANSFUSION; ADVERSE EFFECTS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BLOOD TRANSFUSION REACTION; C57BL MOUSE; EVALUATION STUDY; IMMUNOLOGY; STATISTICAL MODEL; THROMBOCYTE;

ANIMALS; BIOMARKERS; BLOOD PLATELETS; HISTOCOMPATIBILITY ANTIGENS; ISOANTIBODIES; LINEAR MODELS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLATELET TRANSFUSION; TRANSFUSION REACTION;

EID: 84954169074     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13270     Document Type: Article

References (17)

1. Hess JR., Resuscitation of trauma-induced coagulopathy. Hematology Am Soc Hematol Educ Program 2013; 2013: 664-7.
2. Thiagarajan P, Afshar-Kharghan V., Platelet transfusion therapy. Hematol Oncol Clin North Am 2013; 27: 629-43.
3. Pavenski K, Freedman J, Semple JW., HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012; 79: 237-45.
4. Kamphuis MM, Paridaans NP, Porcelijn L, et al., Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics 2014; 133: 715-21.
5. Lewin S, Bussel JB., Review of fetal and neonatal immune cytopenias. Clin Adv Hematol Oncol 2015; 13: 35-43.
6. Thomas KA, Valenzuela NM, Reed EF., The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med 2015; 21: 319-29.
7. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-9.
8. Gilson CR, Zimring JC., Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model. Transfusion 2012; 52: 849-59.
9. Maltzman JS, Turka LA., T cell costimulatory blockade in organ transplantation. Cold Spring Harb Perspect Med 2013; 3: a015537.
10. Carreno BM, Collins M., The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20: 29-53.
11. Gardner D, Jeffery LE, Sansom DM., Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant 2014; 14: 1985-91.
12. Baldo BA., Chimeric fusion proteins used for therapy: indications, mechanisms, and safety. Drug Saf 2015; 38: 455-79.
13. Gilson CR, Patel SR, Zimring JC., CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice. Transfusion 2012; 52: 2209-19.
14. Patel SR, Cadwell CM, Medford A, et al., Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice. J Clin Invest 2009; 119: 2787-94.
15. Ault KA, Knowles C., In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995; 23: 996-1001.
16. Manning KL, Novinger S, Sullivan PS, et al., Successful determination of platelet lifespan in C3H mice by in vivo biotinylation. Lab Anim Sci 1996; 46: 545-8.
17. Fontaine MJ, Kuo J, Chen G, et al., Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. Transfusion 2011; 51: 2611-8.